Replies to post #291830 on NorthWest Biotherapeutics Inc (NWBO)

[FloatServe]

In this video she mentions that she thinks since nearly 90% got the vaccine, this likely turned into a very large single arm trial.

Does anyone think this will be true?

I would assume many two arm oncology trials also have high rates of crossover as well.

Instead of making it into a single arm trial, couldn’t they compare early vs late and then also include a KM curve that adjust for crossover effect?